News >

Sonpavde Navigates the Evolving Bladder Cancer Landscape

Angelica Welch
Published: Wednesday, May 09, 2018

Guru Sonpavde, MD

Guru Sonpavde, MD
In the era of immunotherapy, particularly considering its impact on genitourinary malignancies, many experts are looking to PD-1/PD-L1 inhibitors for their patients with urothelial carcinoma. However, chemotherapy is still a big player in the advanced-disease setting, making the treatment landscape quite varied.

State of the Science Summit™ on Genitourinary Cancers.

Chemotherapy

The biggest unmet need in the bladder cancer space is the treatment of cisplatin-ineligible patients, says Sonpavde. Patients with urothelial carcinoma who are ineligible to receive cisplatin have suboptimal survival with chemotherapy. Given that cisplatin plus chemotherapy improves survival in the advanced disease setting, it makes sense to give neoadjuvant chemotherapy before radical cystectomy in high-risk locally advanced or muscle-invasive bladder cancer, Sonpavde explains.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x